As a GTC shareholder, I like the Teva-CoGenesys deal insofar as it establishes another price benchmark for this kind of acquisition. The $400M price tag is identical to what MRK paid for GlycoFi in 2006 (#msg-11018747).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”